Antibiotics Market Size, Share & Trends Report

Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Protein, DNA, RNA, Cell Wall Synthesis Inhibitors), By Drug Class (Penicillin, Cephalosporins, Fluoroquinolones), And Segment Forecasts, 2019 - 2026

  • Published Date: Feb, 2019
  • Base Year for Estimate: 2018
  • Report ID: GVR-1-68038-149-8
  • Format: Electronic (PDF)
  • Historical Data: 2015 - 2017
  • Number of Pages: 119

Industry Insights

The global antibiotics market size was valued at USD 45.31 billion in 2018 and is projected to expand at a CAGR of 4.0% over the forecast period. Rise in the cases of infectious diseases along with imbalance of demand-supply of antibiotics is the main factor driving the growth this market. Increasing efforts undertaken by major companies for the development of advanced products will also support market growth. According to data published by the Pew Charitable Trust, in March 2016, about 37 promising molecules were being investigated within the U.S. market. Majority of these are in phase II clinical trials and are anticipated to hit the market between 2018 and 2020.

Furthermore, supportive government legislation, such as the Generating Antibiotics Incentives Now (GAIN) Act, are expected to expedite the approval process. GAIN Act has provisions, which facilitate the development of therapies against antibiotic-resistant pathogens. Diarrhea remains the leading cause of death among children across the globe and it requires antibiotic intervention to prevent the morbidity. Other infectious diseases identified to pose high burden are HIV/AIDS, pneumonia, malaria, and tuberculosis. Furthermore, the emergence of new infections, such as the Zika and Ebola virus, are also supporting the development and uptake of antibiotics.

U.S. antibiotics market

Strategic plans of collaborative development to divide the expenses are now being commonly implemented by the market participants. This, in turn, is expected result in the development of more number of molecules. In addition, public-private collaborations, where fund and innovative R&D approaches are advanced by public bodies to antibiotics manufacturers, will further support the generation of new pipeline products. For instance, in September 2015, the Department of Health and Human Services signed a five-year agreement with AstraZeneca, where the former provided USD 220 million for the exploration of 2 molecules namely, Avibactam and Aztreonam.

However, development of resistance, especially in case of bacterial infections, is on the rise and renders the antibiotic or its entire class ineffective, thereby critically impacting the overall market growth. According to researchers, the resistance rate is expected to rise over the forecast period but may vary depending upon the strain, geographies, and patient ethnicity. According to the data published by the CDC in 2015, about 2 million people are affected by antibiotic resistance development causing 23,000 deaths annually.

Action Mechanism Insights

On the basis of mechanism, the market is segmented into cell wall, protein, DNA, RNA, mycolic acid, and folic acid synthesis inhibitors. Majority of the antibiotics, such as penicillins, cephalosporins, and carbapenems, form a part of the cell wall synthesis inhibitors class. Folic acid and RNA synthesis inhibitors are anticipated to witness significant CAGRs over the forecast period. Development of several antiviral drugs, which inhibit transcription and reverse transcription process are anticipated to support the growth. Folic acid inhibitor sulfa drugs are anticipated to grow as they have a wide scope of application.

Drug Class Insights

On the basis of drug class, the market is segmented into cephalosporins, penicillins, fluoroquinolones, macrolides, carbapenems, aminoglycosides, and sulfonamides. The other antibiotics segment comprises of tetracyclines, imidazoles, lincosamides, and monoclonal antibodies. The other antibiotics segment is anticipated to expand at the highest CAGR during the forecast years. The Development of monoclonal antibodies for individuals that have developed antibiotic-resistance is a key highlight of this segment.

Global antibiotics market

Increasing incidence of pneumonia, blood stream infections, and Urinary Tract Infections (UTI) is anticipated to foster the usage of carbapenems class of antibiotics. Growing threat of drug-resistance is leading to the development of newer combinational formulations. For instance, the emergence of multi-resistance tuberculosis and infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) is difficult to treat with antibiotics, therefore, the development of new antibiotics is required.

Regional Insights

North America held a substantial share of the global market in 2018. Healthcare system in the North American region facilitates the usage of branded products, however with the loss of exclusivity of certain molecules, sales in this region eroded significantly in the past few years. Asia Pacific held a significant share in the past on account of large population base, high prevalence of infectious diseases, regulation reforms, and greater usage of generic medicines. Latin America, especially Brazil, with its strong growth in the pharmaceuticals sector is also projected to exhibit remunerative growth. Outbreak of certain viruses, such as Ebola, in the Africa contributed to the growth of the region.

Antibiotics Market Share Insights

Some of the prominent companies in the market are Pfizer, Inc.; Janssen Pharmaceuticals; Abbott Laboratories; GlaxoSmithKline plc; Sanofi S.A.; Novartis AG; Bayer AG; Bristol Myers Squibb Company; Eli Lilly and Company; and Astellas Pharma, Inc. With a very few patented products available currently, generic manufacturers are leading the market.

Key marketing strategies undertaken by most of these firms include product development, regional expansion, and collaborative development. For instance, In August 2016, Pfizer entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infective business, mainly outside U.S.

Report Scope

Attribute

Details

Base year for estimation

2018

Actual estimates/Historical data

2015 - 2017

Forecast period

2019 - 2026

Market representation

Revenue in USD Million and CAGR from 2019 to 2026

Regional scope

North America, Europe, Asia Pacific, Latin America, and MEA

Country scope

U.S., Canada, Germany, U.K., France, Italy, Spain, China, Japan, India, Thailand, South Korea, Brazil, Mexico, Argentina, Columbia, South Africa, Saudi Arabia, and UAE

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global antibiotics market report on the basis of action mechanism, drug class, and region:

  • Action Mechanism Outlook (Revenue, USD Million, 2015 - 2026)

    • Cell Wall Synthesis Inhibitors

    • Protein Synthesis Inhibitors

    • DNA Synthesis Inhibitors

    • RNA Synthesis Inhibitors

    • Mycolic Acid Inhibitors

  • Drug Class Outlook (Revenue, USD Million, 2015 - 2026)

    • Cephalosporin

    • Penicillin

    • Fluoroquinolone

    • Macrolides

    • Carbapenem

    • Aminoglycosides

    • Sulfonamides

    • Other

  • Regional Outlook (Revenue, USD Million, 2015 - 2026)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

    • Asia Pacific

      • China

      • Japan

      • India

      • Thailand

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

    • MEA

      • South Africa

      • Saudi Arabia

      • UAE

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $6,950
Enterprise Access - $8,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified